Retrovirology



Oral presentation Open Access

HIV-I antagonism of CD3 I 7/tetherin is species-specific and involves Vpu-mediated proteasomal degradation of the intrinsic immunity factor

Christine Goffinet¹, Ina Allespach¹, Stefanie Homann¹, Hanna-Mari Tervo¹, Anja Habermann¹, Daniel Rupp¹, Lena Oberbremer¹, Christian Kern¹, Nadine Tibroni¹, Sonja Welsch^{1,2,3}, Jacomine Krijnse-Locker^{1,2}, George Banting⁴, Hans-Georg Kräusslich¹, Oliver T Fackler¹ and Oliver T Keppler*¹

Address: ¹Department of Virology, University of Heidelberg, Germany, ²EMBL, Cell Biology and Biophysics Program, Heidelberg, Germany, ³Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK and ⁴Department of Biochemistry, University of Bristol, UK

from Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts Montpellier, France. 21-23 September 2009

Published: 24 September 2009

Retrovirology 2009, 6(Suppl 2):O10 doi:10.1186/1742-4690-6-S2-O10

This abstract is available from: http://www.retrovirology.com/content/6/S2/O10

© 2009 Goffinet et al: licensee BioMed Central Ltd.

Mammals encode proteins that inhibit viral replication at the cellular level. In turn, certain viruses have evolved genes that can functionally counteract these intrinsic restrictions. Human CD317 (BST-2/tetherin) was recently identified as a restriction factor that blocks release of HIV-1 from the cell surface and can be overcome by HIV-1 Vpu. Here, we show that mouse and rat CD317 potently inhibit HIV-1, but are resistant to Vpu. To promote virus release, Vpu depletes cellular pools of human CD317, but not of the rodent orthologs, by accelerating its degradation via the 20S proteasome. Importantly, HIV-1 downsurface-exposed CD317 and endogenous pools of the restriction factor in infected human T-cells in a Vpu-dependent manner. Distinct mutants of CD317 indicate that also degradation-independent abilities of Vpu contribute to its ability to promote virus release. Interspecies-chimeras of CD317 reveal that the rodent-specific resistance and human-specific sensitivity to Vpu antagonism have a complex genetic basis involving all three major structural domains of the restriction factor. In rodent cells, knock-down of endogenous CD317 enhances HIV release and accelerates MLV

spread, suggesting that CD317 contributes to the control of retroviral pathogenesis. Thus, HIV-1 Vpu suppresses the expression of the CD317 antiviral factor in infected human cells, and the species-specific resistance to Vpu antagonism may guide the advancement of small animal models of HIV infection.

^{*} Corresponding author